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Background: Non-adherence with antipsychotic medication is a frequently occurring problem, particularly among
patients with psychotic disorders. Prior research has generally shown encouraging results for interventions based on
‘Contingency Management’ (CM), in which desirable behaviour is encouraged by providing rewards contingent
upon the behaviour. However, little is known about the application of CM on medication adherence in patients
with psychotic disorders. An earlier pilot-study by our study group showed promising results in reducing admission
days and increasing adherence. The current study is a randomized controlled trial concerning the effectiveness of a
CM procedure called ‘Money for Medication’ (M4M), aimed at improving adherence with antipsychotic depot medication
in psychotic disorder patients.
Methods/Design: Outpatients (n =168) with a psychotic disorder will be randomly assigned to either the experimental
group (n =84), receiving a financial reward for each accepted antipsychotic medication depot, or the control group
(n =84), receiving treatment as usual without financial rewards. Patients are included regardless of their previous
adherence. The intervention has a duration of twelve months. During the subsequent six months follow-up, the effects
of discontinuing the intervention on depot acceptance will be assessed.
The primary goal of this study is to assess the effectiveness of providing financial incentives for improving adherence
with antipsychotic depot medication (during and after the intervention). The primary outcome measure is the
percentage of accepted depots in comparison to prescription. Secondary, we will consider alternative measures of
medication acceptance, i.e. the longest period of uninterrupted depot acceptance and the time expired before depot is
taken. Additionally, the effectiveness of the experimental intervention will be assessed in terms of psychosocial
functioning, substance use, medication side-effects, quality of life, motivation, cost-utility and patients’ and clinicians’
attitudes towards M4M.
Discussion: This RCT assesses the effectiveness and side-effects of financial incentives in improving adherence with
antipsychotic depot medication in patients with psychotic disorders. This study is designed to assess whether M4M is
an effective intervention to improve patients’ acceptance of their antipsychotic depot medication and to examine how
this intervention contributes to patients’ functioning and wellbeing.
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Consequences of non-adherence
Approximately 60% of patients with psychotic disorders
experience difficulties being adherent over time or fail
to take their medications as prescribed, with mean
non-adherence rates around 50% [1-3]. Moreover,
among patients who do not openly refuse to accept
their antipsychotic medication, many are only partially
adherent [4]. Failure to take the medication as prescribed
is associated with a wide array of adverse individual and
societal outcomes such as inconsistent symptom control,
more relapses [5-7], more (re)hospitalizations [8,9], more
suicide attempts [10,11] and more encounters with police
and justice, either as a victim or as a perpetrator [12].
Clinical advantages of antipsychotic medication are
often limited by patients’ failure to adhere sufficiently to
their prescribed medication. This partial compliance
severely reduces the effectiveness of the medical treatment
of schizophrenia and interferes with therapeutic efforts
[13]. For example, relapses occur within one year for 50 to
75% of the patients with schizophrenia after discontinuing
with their antipsychotics [14]. Missing antipsychotic
medication has also been associated to double the
risk for hospitalization [9]. Throughout this protocol
alternative definitions such as ‘acceptance’ or ‘compliance’
relate to the concept of medication adherence.
Risk factors for non-adherence
Risk factors for non-adherence have been studied
extensively and were systematically reviewed by Higashi
and colleagues [15]. They distinguished (1) patient-, (2)
treatment-, and (3) environmental-related factors to be
associated with non-adherence.
(1) Patient-related factors included poor insight,
negative attitudes towards medication, obesity,
previous non-adherence and a shorter duration of
illness. Furthermore, comorbid substance use
disorders - particularly prevalent in patients with
psychotic disorders (70–80%) [16] were also associated
with increased non-adherence [9,17-19]. In addition,
temperamental characteristics like sensation seeking
and disinhibition predicted poor medication adherence
in patients with psychotic or mood disorders [20].
From this perspective it is important to also study the
(moderating) effects of impulsivity and substance use
on the effectiveness of the M4M intervention because
certain subgroups of patients could respond differently
to the intervention (e.g. impulsive patients perhaps
profit less from our intervention since they have more
difficulties regulating their behavior). Therefore, this
study investigates the role of impulsivity and substance
use disorders in patients with psychotic disorders and
their associated medication adherence.(2) Treatment-related risk factors for non-adherence
included distress by side effects of the medication
[21], higher antipsychotic doses and the use of
classical antipsychotic medications [22,23].
(3) Environmental-related risk factors included stigma
of taking medication, lack of support [24], poor
therapeutic relationships, financial problems, chaotic
living situations and poor aftercare [21,25].
Interventions to improve compliance
Unfortunately, most studies investigating interventions
to improve adherence yield inconsistent results and do
not always lead to less symptoms, better functioning or
improved quality of life [26,27]. Therefore, a (combination)
of innovative methods is needed to help patients take their
antipsychotic medication as prescribed [28-30]. One such
innovative intervention is contingency management.
Contingency Management (CM) interventions typically
reinforce pre-set, well-defined and verifiable target behaviors
(e.g., drug abstinence or medication intake), by providing
financial incentives or vouchers. Interventions based
on CM-principles have been applied in various settings
targeting a variety of behaviors, and have shown robust
effects in reducing drug use and increasing treatment
compliance and medication adherence (for overviews
see; [31,32]). Currently, no studies have investigated the
effect of CM for non-depot medication adherence in
patients with schizophrenia.
In reviewing studies using CM based interventions in
patients with mental health problems, Priebe et al. [33]
did not find any randomized controlled studies testing
the effectiveness of financial incentives to improve
depot medication adherence in patients with psychotic
disorders. However, two pilot studies were conducted
that showed promising results.
Claassen and colleagues [34] included five non-adherent
patients of which four patients accepted financial incentives
upon medication acceptance. This resulted in improved
adherence rates and significantly decreased patients’
hospital admissions during the intervention period.
Staring et al. [35], also included five non-adherent patients
with psychotic disorders in their pilot study. Results
showed that the percentage of accepted depot injections
increased from an average of 44% in the previous year to
100% in the year in which financial incentives were
offered. While patients had been hospitalized for an
average of 100 days in the preceding year, only one
patient was re-admitted for 17 days during the intervention
year. More recently, the first cluster randomized controlled
trial tested the effectiveness of offering financial incentives
to patients (n = 141) with psychotic disorders who were
partially non-compliant to improve their medication
adherence [36]. Interestingly, although adherence to
antipsychotic depot medication increased significantly
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(85% and 69% acceptance of depot after one year),
this did not result in a significant difference on clinician
rated clinical improvement. In sum, two pilot studies
showed promising results and one RCT showed partial
positive results of financial incentives upon acceptance of
antipsychotic depot medication.
Study objectives
The goal of the current study is to assess the effectiveness
of providing financial incentives upon depot acceptance in
psychotic disorder patients. The primary objective of this
study is to assess the effectiveness of M4M during the inter-
vention in terms of acceptance of antipsychotic depot
medication (the medication possession ratio; MPR). To
assess how discontinuing the intervention affects depot
acceptance, we will also compare the MPR during the
follow-up period (six months), in which no CM takes place.
In addition to the MPR, secondary objectives include the
longest uninterrupted period of depot medication accept-
ance, the expired time before depot is taken and attitudes
towards medication. Our third objective is to assess the
effects of medication acceptance on patients psychosocial
functioning, quality of life, cost-utility, substance use and
side effects of the antipsychotic medication.
Hypotheses
The primary hypothesis is that M4M results in signifi-
cantly more accepted depots than treatment as usual
(TAU). Patients from both the TAU and M4M condition
are prescribed antipsychotic depot medication. Secondary
hypotheses are that M4M, compared to TAU, leads to (1)
longer uninterrupted periods of depot acceptance and (2)
less time expired before the depot is taken. From our
tertiary measures, we expect M4M (compared to
TAU) to result in (3) less severe symptoms and better
psychosocial functioning, (4) improved quality of life,
(5) less substance use, and (6) lower costs.
Using exploratory analyses we will look for patient
characteristics (at baseline) – the stratification variables
(gender, comorbid substance use, and medication adher-
ence) and, other variables including impulsivity, motivation
and attitudes towards antipsychotic medication and
M4M – that could moderate the effects of M4M and
might be used for future patient treatment matching. In
addition, we will explore the role of potential mediating var-
iables – e.g., medication side effects – in M4M’s effective-
ness. Finally, we will analyze self-reported data on patients’
and clinicians’ perceptions of M4M. This enables us
to discuss the ethical considerations of M4M.
Methods
The contents of the study design, data collection, analyses,
interpretation of data, writing of the manuscript and thedecision to submit the manuscript for publication was not
influenced by the funding body (Palier, department of
Parnassia Psychiatric Institute).
Study design
In a parallel-group randomized controlled trial, patients
will be randomly assigned to the experimental condition
(M4M), or to the treatment as usual (TAU) control condi-
tion. Note that during the recruitment phase of the study,
only patients who are prescribed or have an indication for
antipsychotic depot medication, and who have expressed
their willingness to accept antipsychotic depot medication
are eligible for inclusion and after providing written
informed consent for randomization. Patients assigned to
the experimental condition (M4M, n =84) will receive a
financial incentive for each prescribed depot they accept,
in addition to treatment as usual. Patients in the control
condition (TAU, n =84) will receive treatment as usual
only without financial incentives upon depot acceptance.
After randomization, both patients in the TAU condition
and patients in the M4M condition are prescribed depot
medication. After the intervention period of 12 months,
there will be a follow-up period of 6 months in which
patients in both study groups receive TAU and no financial
incentives for accepting their prescribed antipsychotic
depot medication.
Participants/Setting
Patients will be 168 outpatients with a psychotic dis-
order from three mental health care institutions in
the Netherlands: (1) Palier (‘Dual Diagnosis Centre’
(CDP)), (2) Parnassia and (3) BavoEuropoort. These
organizations primarily treat patients with psychotic
and other severe mental disorders, (often with comorbid
substance use disorder), from the cities of Rotterdam and
the Haque in the Netherlands. Per team around two
hundred patients with a psychotic disorder are treated.
Patients will be recruited based on the following inclusion
criteria: age between 18 – 65 years, a psychotic disorder
(including schizophrenia, schizoaffective disorder or other
psychotic disorders), taking antipsychotic depot medica-
tion or an indication to start using depot medication,
outpatient treatment (either starting outpatient treatment
after discharge from a psychiatric hospital, or being in
outpatient treatment for at least four months), and given
informed consent. In concordance with their psychiatrist,
patients who will start using antipsychotic depot medica-
tion are considered to have an indication for antipsychotic
depot medication. These patients are - if they meet the
other inclusion criteria- eligible to contact for our study.
Exclusion criteria are the inability to participate due to
cognitive impairments and/or insufficient understanding
of the Dutch language (clinical judgment). Refer to
Figure 1 Participant flowchart for details.
Assessed for eligibility
(n = )
Randomization (n = )
Analyzed (n = )
Excluded from analysis
(n = )
For reason
Analysis
Lost to follow-up (n = )
For reason
Lost to follow-up (n = )
For reason
Discontinued
intervention (n = )
For reason
Follow-up 18 months
Follow-up 12 months
AllocationAllocated to intervention
(n = )
Received intervention
(n =)
Did not receive 
intervention (n = )
For reason
Excluded (n = )
No dual diagnosis (n = )
Oral antipsychotic 
medication (no depot)
(n = )
Not missed or too late 
for 50% of prescribed
depots (n = )
Not willing to participate 
(n = )
Not able to provide 
informed consent (n = )
Other reasons (n = )
Analyzed (n = )
Excluded from analysis
(n = )
For reason
Lost to follow-up (n = )
For reason
Lost to follow-up (n = )
For reason
Allocated to control 
(n = )
Figure 1 Participant flowchart.
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Patients assigned to the intervention group (M4M;
Money for Medication) will receive treatment as usual
(see below), plus a financial incentive for each time they
accept their prescribed depot of antipsychotic medication
during the 12 months experimental study phase. All
patients in the M4M group will receive a maximum of 30
euro per month. The amount of money per accepted depot
is dependent upon the frequency of depot administration.For example, a patient who receives one depot every two
weeks will receive 15 euro per accepted depot. A patient
who receives one depot every three weeks will receive
22.50 euro for each accepted depot, et cetera. Patients
receiving oral penfluridol with a frequency of once a week
will also be included in the study. Oral penfluridol is used
when patients have problems taking antipsychotic medica-
tion on a daily basis, and when they do not accept intra-
muscular depot injections. They will receive 7.50 euro for
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The financial incentives will be given by the patients’
treating nurses directly upon administration of the
depot or penfluridol. They will receive their depot
medication primarily at the clinic (‘depot room’) and
sometimes at home during home visits. Patients will
sign a proof of receipt.
Patients assigned to the control group will receive treat-
ment as usual (TAU) during the 12 months experimental
study phase and during the 6 months follow-up. TAU
includes outpatient treatment provided by community
mental health teams and flexible assertive community
treatment teams [37]. All clinicians encourage continuing
depot medication in case this is prescribed by the
psychiatrist of the team. When needed, crisis services can
be used or patients can be hospitalized (in)voluntarily. The
type and dosage of the depot antipsychotic medication and
other medications patients receive will be determined by
the patients’ psychiatrist together with the patient. The
type, frequency and dosage will not be affected by participa-
tion in the study. Administration of the depots will be done
by the psychiatric nurses working in the teams.
Procedure
Candidate participants will be selected from the caseloads,
applying the in- and exclusion criteria. Patients who meet
the criteria will be informed and asked to participate by
their clinician. Patients who consider participation receive
a take-home brochure with information about the study.
The clinician asks the patient’s permission to be contacted
by a researcher. If the patient agrees, the researcher
contacts the patient to schedule an appointment for
the baseline interview. If a patient indicates that he or she
does not want to participate, this will be registered
anonymously together with their demographic and clinical
characteristics (DSM IV-TR diagnosis on axes I and II) to
enable assessment of selection bias. If possible, the patient
will be asked to explain why he or she does not want to
participate.
With support of the management, all teams and their
clinicians have expressed their willingness to co-operate
with the conduct of our Money for Medication study.
Clinicians of course can be resilient about the concept and
intervention of our study. Therefore, we assess clinicans’
attitudes towards M4M.
Prior to the baseline interview the researcher explains
the design and purpose of the study, the research goals and
the randomization procedure. After written informed
consent is given, the baseline interview will take place
and subsequently, participants will be randomized to
the intervention (M4M) or control condition (TAU).
Randomization will be stratified by site, gender, substance
use disorder (absent vs. prevalent) and previous compliance
with antipsychotic medication (compliance rate <50%vs. ≥50%). There will be three interviews at 0, 12 and
18 months (see Table 1). All participants will receive
a remuneration of 20 euro for each interview. In the
cases where the researchers cannot overcome certain
practical obstacles (e.g. imprisonment, hospitalization),
patients who can demonstrate that they have accepted
their depot medication (for instance in the form a
written statement by the treating prison or hospital
medical doctor), receive their monetary reward as soon as
possible, but with a delay. In case of discontinuation of
depot intake, the monetary reward will stop and data of
non-depot medication intake will be monitored in
order to have a complete overview on the number of
patients discontinuing depot medication and switching
to non-depot.
Originally the start date for patient recruitment was
May 21, 2010 and was planned to be completed by
September 2012. Due to a change in personnel and
organizational factors that caused logistical delays, patient
recruitment was low and continued again in September
2013. Note that this is an ongoing study and that we
expect to finish our complete data collection by April
2016. Therefore, we expect to submit the results of
this study in 2016.
Instruments
Baseline variables
Demographic variables, DSM-IV diagnoses on Axis I
and II, and psychiatric history (including hospitalizations
during the last three years, current antipsychotic and
concomitant medication, and antipsychotic depot accept-
ance 4 months before the study) will be collected in the
first interview and from patients’ records.
Outcome measures
1. Primary outcome measure: The primary outcome
measure is medication acceptance, represented by
the percentage of accepted depot injections. This is
defined as the ‘Medication Possession Ratio’ (MPR)
first reported by Sclar, Chin and Skaer [38]. The
MPR is the number of accepted depots antipsychotic
medication divided by the number of prescribed
depots antipsychotic medication (the number of
supplies needed for continuous use of antipsychotic
medication).
2. Secondary outcome measures: The secondary
outcome measures include additional measures of
adherence, including the longest uninterrupted
period of depot medication acceptance, the time
expired before the depot is taken and patients
attitudes towards medication.
a. Longest uninterrupted period of depot medication
acceptance: Sometimes occasional missed doses are
Table 1 Measures and instruments and assessment times
Category Outcome measure Instrument Assessment (month)
0 12 18
Demographics Registration forms X
Medication acceptance - Percentage accepted depots (MPR) Registration forms Continuously Continuously Continuously
- Longest uninterrupted period Registration forms Continuously Continuously Continuously
- Time expired before depot is taken Registration forms Continuously Continuously Continuously
- Attitudes towards medication ROMI X X X
Psychosocial functioning - Psychiatric symptomatology PANSS X X X
- Health, psychological and
social functioning
HoNOS X X X
- Substance use ASI X X X
CIDI-SAM X
Urine screens X X X
- Quality of Life MANSA X X X
- Antipsychotic side-effects ASC X X X
- Treatment Entry Questionnaire TEQ X X X
- Dickman Impulsivity questionnaire DII X X X
Cost-utility - Health-care consumption TiC-P X X X
- Health-related quality of life EQ-5D X X X
- Self-reported delinquent behaviour SRD X X X
- Effort of clinicians Registration forms Continuously Continuously Continuously
Ethical aspects - Attitudes towards M4M Questionnaire constructed
for the current study
X X X
ROMI: Rating Of Medication Influences, PANSS: Positive And Negative Symptoms Scale, HoNOS: Health of the Nations Outcome Scales, ASI: Addiction Severity
Index, CIDI-SAM: Composite International Diagnostic Interview – Substance Abuse Module, MANSA: Manchester Short Assessment of Quality of Life, ASC:
Antipsychotic Side-effects Checklist, TEQ: Treatment Entry Questionnaire, TiC-P: Trimbos/iMTA questionnaire for Costs associated with Psychiatric Illness,
EQ-5D: EuroQol-5D, Quality of Life, SRD: Self-Reported Delinquency questionnaire.
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even partial adherence can severely undermine
clinical improvement [9] it is important to strive for
continuous medication adherence. Therefore, the
longest uninterrupted period of medication
acceptance will be assessed as well. In sum, this
outcome measures the time period (number of
days/weeks) a patient takes the prescribed
antipsychotic depot medication according to
schedule, without missing or not taking a single
depot prescription).
b. Time expired before depot is taken: Following Priebe
et al. [33], we will monitor the time that has expired
before the patient accepts the prescribed depot.
Note that all patients receive depot medication
(M4M and TAU) according to their own schedule
(i.e., every 14 days). This variable (time expired
before depot is taken) allows us to see whether
patients are late for their prescribed depot. The time
‘slippage’ of taking depots is defined as the
percentage of the prescribed time interval that has
expired before the depot is taken.c. Attitudes towards medication: To assess how patients
attitudes towards medication relate to the effectiveness
of M4M, the ‘Rating of Medication Influences’ (ROMI)
scale [40] will be used. The ROMI measures attitudinal
and behavioral factors influencing patient adherence
with neuroleptic treatment. The ROMI consists of
three subscales related to adherence (prevention,
influence of others and medication affinity) and five
subscales related to non-adherence (denial/dysphoria,
logistical problems, rejection of label, family influence
and negative therapeutic alliance). In sum, the ROMI
asks questions about the reasons for taking medication
and patients’ general attitudes towards treatment. An
example item: “Do you have a positive relation with the
clinical staff?” Patients can answer yes/no and indicate
to what extent this affects their medication intake
(no/some/strong).
3. Tertiary outcome measures: The tertiary outcome
measures include measures on the effects of
medication acceptance on patients psychosocial
functioning, substance use, quality of life and
side-effects of the antipsychotic medication:
Noordraven et al. BMC Psychiatry 2014, 14:343 Page 7 of 11
http://www.biomedcentral.com/1471-244X/14/343a. Psychiatric symptomatology: Psychiatric
symptomatology will be assessed by trained
interviewers with the Dutch version of the ‘PANSS’,
the Positive and Negative Syndrome Scale, originally
conceived by Kay, Fiszbein and Opler [41]. The
PANNS consists of three subscales: positive
symptoms (7 items), negative symptoms (7 items)
and general psychopathology (16 items, including
anxiety and depression). Items are scored on a scale
from 1 (symptom absent) to 7 (symptom interferes
with almost all aspects of daily functioning). Internal
and external consistency of the PANNS has been
found to be adequate [42-44].
b. Health, psychological and social functioning: To
assess patients’ health and psychosocial functioning,
the Dutch translation of the Health of the Nations
Outcome Scales (‘HoNOS’) [45,46] will be
administered by trained interviewers. The HoNOS is
a structured interview to quantify health and social
functioning during the last two weeks on four
subscales (behavioural problems, impairments,
symptoms and social problems). Items are rated on
a 5-point scale ranging from 0 (no problems) to 4
(severe to very severe problems).
c. To test for the potential modifying effect of
impulsivity on the M4M intervention, we will assess
impulsivity by means of the Dickman Impulsivity
Inventory (DII) [47], which has been validated for
the Dutch situation [48] and has good psychometric
properties among substance users as well [49]. The
DII consists of 24 dichotomous items, resulting in a
“functional impulsivity” and a “dysfunctional
impulsivity” score.
d. Substance use: Substance use will be assessed with
the ‘Alcohol and drug use’ section of the European
version of the ‘Addiction Severity Index’ (‘EuropASI’)
[50] and the Substance Abuse Module of the
International Diagnostic Interview [51]. The CIDI is
a structured interview based on the criteria and
definitions of the ICD-10 and DSM-IV with good
psychometric properties [52]. Self-reported drug-use
will be verified by urinanalysis sticks at baseline,
12 and 18 months (follow-up) for amphetamines,
benzodiazepines, cocaine, morphine/heroin and
cannabis.
e. Subjective Quality of Life: To assess patients’
subjective quality of life we will use the third section
of the ‘Manchester Short Assessment of Quality of
Life’ (‘MANSA’) [53]. The MANSA assesses the
patients subjective ratings of life in general and
satisfaction with several more specific domains of
quality of life, including work or education related
issues, financial situation, social relations, leisure
activities, accommodation, family situation, personalsafety and physical and mental health. Items are
rated on a seven-point scale ranging from 1
(could not be worse) to 7 (could not be better). The
MANSA has good psychometric properties [53,54].
f. Antipsychotic Side-effects: To assess how medication
affects patients’ subjective wellbeing, we will use the
17-item Dutch translation of the ‘Antipsychotic
Side-effect Checklist’ (‘ASC’) [55]. The ASC-C is a
checklist designed for mental health clinicians to use
as a brief interview to check for common problems
(side-effects) associated with the use of antipsychotic
medication during a regular therapeutic session.
Items are rated as: symptom present or symptom
absent.
g. Cost-utility: The cost-utility of M4M will be
compared with treatment as usual. To estimate
direct health care from a societal perspective, costs
will be determined and calculated by multiplying
resource use with official charge standards. Our
focus will be on patients’ health care consumption
(admissions, contacts with clinicians, and efforts
initiated to provide depots) and illegal activities.
Measures will be collected from the patients file
and the Trimbos/iMTA self-report questionnaire
for Costs associated with Psychiatric Illness
(TiC-P; [56]), a questionnaire for Self-Reported
Delinquency (SRD, adapted from the INternational
CAnnabis Need of Treatment (INCANT) study),
and the depot acceptance registration forms.
h. QALY’s will be assessed using the EQ-5D: The
EQ-5D is a standardized instrument that scores
health-related quality of life on five levels of health
(mobility, self-care, daily activities, pain/discomfort and
anxiety/depression), which generates a score for
health-related quality of life that can be used as a
weight to calculate Quality Adjusted Life Years or
‘QALY’s’ [57], a weighted health-index. The EQ-5D has
been shown to have good discriminative and construct
validity and to be sensitive in detecting changes in QoL
ratings in patients with substance use [58].
i. Time spent by clinicians to provide depot: To assess
how M4M affects patients’ willingness to accept their
antipsychotic depot medications, the time and effort
spent by the clinicians to provide the depot (e.g. calling,
home visits, et cetera) will be monitored with standard
registration forms designed for the current study.
j. Attitudes towards M4M: In addition to the outcome
measures above, patients’ and clinicians’ attitudes
towards M4M will be assessed with a short
questionnaire constructed for the current study.
Items address different attitudes towards M4M
in terms of its advantages and disadvantages
(e.g. effects on motivation, insight, wellbeing, depot
acceptance, dependency, the relationship between the
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practical considerations). Items will be scored on a
5-point scale (1 = strongly disagree, 5 = strongly agree).
k. Intrinsic and extrinsic motivation: To measure
patients” intrinsic and extrinsic motivation during
the study, the Dutch version of the Treatment Entry
Questionnaire (TEQ) is being used, which has good
psychometric properties [59]. On 27 statements
regarding motivation for the current intervention
patients answer if they agree (1 = strongly disagree,
7 = strongly agree).
Ethical approval
The study protocol has been approved by the accredited
Dutch Medical Ethical Trial Committee (METC) of the
Erasmus University Medical Centre (registered under
number NL31406.097.10 and file number P13.258).
According to the Dutch Data Protection Act (DPA)
data will be safely stored and anonymized and is only
accessible for members of the research group or the
Medical Ethical Committee. All patients will provide
informed consent before entering the study.
Sample size/power
Following the CONSORT statement we calculated our
power to the primary outcome measure of this study and
not for the secondary or tertiary outcome measures. Based
on previous findings and study protocols [33,60], we expect
a difference of 65 to 85 percent (an absolute difference of
20%) of accepted depots between the control group and the
money-for-medication condition. In terms of Cohen’s h,
this constitutes a medium effect size (h =0.5). With Type I
error rate (alpha) set at 5%, power at 0.90 (1 – Type II Error
rate; 1-β), and 20—25% drop-out, we will need 84 patients
per arm to detect an absolute difference of 20% [61]. In
total 168 patients will be included.
Statistical analyses
The primary outcome will be reported as accepted depots
as percentage of planned depots, most often weekly,
biweekly or monthly. The effects of the intervention on our
outcome measures will be analysed using generalized linear
models as appropriate to the outcome, with random effects
for sites or treatment teams. Sensitivity analyses will be
conducted to explore the impact of different strategies for
handling missing data. A detailed analysis plan will be com-
pleted prior to analysis of baseline measurements.
Discussion
The aim of the current randomized controlled study is to
assess the effectiveness of financial incentives (M4M), com-
pared to treatment as usual, in improving the acceptance of
antipsychotic depot medication in patients with psychotic
disorders. Our primary outcome measure will be the MPR.Secondary outcome measures include patients’ health,
social and psychological functioning and subjective
quality of life. Tertiary measures are used to assess the
effects of medication acceptance on patients’ psychosocial
functioning, substance use, quality of life and side effects
of the antipsychotic medication. This allows us to assess
not only whether M4M is an effective intervention to
improve acceptance, but also to what extent medication
acceptance contributes to patients’ wellbeing We will
also compare the MPR during the follow-up period
(six months), in which no CM takes place.
The use of financial incentives in M4M
In the pilot study of Claassen et al. [34], M4M did not
have a negative impact on the therapeutic relationship.
Furthermore, they have not found that other patients
who did not participate in the M4M study complained
about unequal treatment or demanded to be paid for taking
medication as well.
In the pilot study of Staring, Mulder, and Priebe [35], all
five participants considered M4M to be a good project. The
reasons they gave to participate in the pilot were “I don’t
like the injection, but money makes it better”, “Money
keeps me motivated”, and “The depot injections keep me
balanced”. When prompted, two patients said that they per-
ceived financial incentives as a voluntary and non-coercive
measure, two patients did not know what to think about
this, and one indicated that he perceived financial incen-
tives as a coercive measure, saying that “I have to take the
medication anyway”. All patients said that they spent the
money on food and cigarettes, and one patient also bought
household products. It was observed, however, that at least
one patient had spent some of the money on cannabis.
Other patients did not ask to be offered incentives as well
and no negative impacts on therapeutic relationships were
noted. Some patients however felt that they should receive
more money (they received 10 euro for every two weekly
depot, 15 euro for every three-weekly depot and 20 euro
for every four-weekly depot).
Although higher payments have been found to result in
bigger effects [62,63], in the present study we have chosen a
maximum of 30 euro’s on average per month because (1)
patients could get used to or become financially dependent
on higher payments or even lose their social security bene-
fits and (2) to strive for acceptable cost-utility of M4M.
From a societal perspective it is important to focus on cost-
effective interventions and given the results of prior research
[35], it seems not necessary to use higher incentives.
Strengths and limitations
Our study started in 2010, prior to some of the recent
findings as described above. The difference with the earlier
RCT studying the effects of M4M [36] is that we will
include both patients who are partially non-compliant, as
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medication. The rationale to also include compliant
patients is the observation in several studies that around
thirty percent of patients initiated on antipsychotic depot
medication cease to accept their depot within one year
[5,64,65]. In addition, when we eventually might want to
implement this intervention into daily clinical practice, it
is more ethical as well as more practical to reward both
compliant and non-compliant patients.
A possible limitation of this study are the different
medication depots. Although most patients receive medi-
cation injections it is also allowed for patients to take oral
penfluridol. The disadvantage of this oral antipsychotic
medication is that it is more difficult to check if patients
actually take their medication. However, penfluridol is also
a depot and because we aim to test if our intervention is
broadly applicable we decided to include both patients
with oral penfluridol and injections.
Another limitation is that the clinicians cannot be
blinded to the intervention condition, possibly resulting in
a more stimulating attitude for accepting depot medica-
tion in the intervention group. Also, the interviewers are
not blind to the patients’ condition and therefore can rate
patients’ responses as more positive or negative.
Furthermore, the intervention effect can be influenced
by different depot frequencies. For example, patients
who receive money every week are rewarded four times
as often compared to patients that receive depot every
month. Receiving a small incentive more frequently can be
more stimulating or motivating compared to receiving a
bigger incentive only once a month. This can interfere with
our intervention effect, even though the mean amount of
money per month remains equal for all participants.
Ethical issues
Ethical concerns have been raised about paying patients
to accept their medication and whether this is an accept-
able means in the treatment of patients with psychotic
disorders [66,67]. One of these concerns is that patients’
intrinsic motivation to accept medication will disappear
if money is involved. We will study this by assessing
intrinsic motivation over time, as possible decreases
in depot acceptance can occur during the 6 month
follow-up without M4M. Another frequently raised
ethical argument is that patients might buy drugs or
alcohol from the money they receive. We will monitor
alcohol and drug use by using assessment scales as well as
obtaining urine samples.
Apart from these ethical concerns, we will also assess
the intervention from a cost-utility perspective, because
this is an important factor to consider from a societal
point of view. In conclusion, we will test if M4M improves
patients’ MPR, reduces their psychotic symptoms and
contributes to a clinical improvement.Competing interests
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